Methods of treating and preventing amyotrophic lateral sclerosis
US-2019038659-A1 · Feb 7, 2019 · US
Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody
US10723787B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10723787-B2 |
| Application number | US-201816478576-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 19, 2018 |
| Priority date | Jan 20, 2017 |
| Publication date | Jul 28, 2020 |
| Grant date | Jul 28, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of alleviating or inhibiting the progress of symptoms of sporadic amyotrophic lateral sclerosis (ALS) by neutralizing a HERV-K envelope protein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody that recognizes the HERV-K envelope protein, wherein said antibody comprises a light chain comprising a light chain variable region (VL) which comprises three complementarity determining regions (CDR-L1, CDR-L2 and CDR-L3), and a heavy chain comprising a heavy chain variable region (VH) which comprises three complementarity determining regions (CDR-H1, CDR-H2 and CDR-H3), wherein the CDR-L1 comprises the amino acid sequence of SEQ ID NO:1, the CDR-L2 comprises the amino acid sequence of SEQ ID NO:2, the CDR-L3 comprises the amino acid sequence of SEQ ID NO:3, the CDR-H1 comprises the amino acid sequence of SEQ ID NO:4, the CDR-H2 comprises the amino acid sequence of SEQ ID NO:5 and the CDR-H3 comprises the amino acid sequence of SEQ ID NO:6. 2. The method according to claim 1 , wherein the light chain variable region (VL) comprises the amino acid sequence of SEQ ID No: 7; and the heavy chain variable region (VH) comprises the amino acid sequence of SEQ ID No: 8. 3. The method according to claim 1 , wherein said antibody is humanized. 4. The method according to claim 1 , wherein said antibody is a murine monoclonal antibody.
Assignees
Inventors
Classifications
Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title
- C07K16/112Primary
Retroviridae (F), e.g. leukemia viruses · CPC title
with immune complex formed in liquid phase · CPC title
Demyelinating diseases; Multipel sclerosis · CPC title
Immunoassays for the detection of microorganisms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10723787B2 cover?
- The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.
- Who is the assignee on this patent?
- Geneuro Sa, Us Health
- What technology area does this patent fall under?
- Primary CPC classification C07K16/112. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).